Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
Rhea-AI Summary
Repligen (NASDAQ:RGEN) will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco, January 12–15, 2026.
Olivier Loeillot, President and CEO, will deliver an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast will be available on Repligen’s investor relations website and will be replayable for a limited period after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RGEN gained 0.51%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Medical Instruments & Supplies show mixed modest moves, with names like ATR and STVN up while BLCO is slightly down, suggesting today’s setup for RGEN is more stock-specific than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 16 | Product launch | Positive | -1.6% | Launch of three new high-performance chromatography resins for gene therapy workflows. |
| Nov 26 | Conference appearance | Neutral | -0.3% | Planned participation in Evercore Healthcare Conference with webcast access. |
| Nov 04 | Multiple conferences | Neutral | -2.2% | Attendance at five November investor conferences with executive presentations. |
| Oct 28 | Earnings, guidance | Positive | -5.9% | Q3 2025 beat with guidance raised and broad-based double-digit growth reported. |
| Oct 15 | Earnings scheduling | Neutral | +0.8% | Announcement of Q3 2025 reporting date and related conference call details. |
Recent positive operational and earnings updates on Oct 28 and Dec 16 were followed by negative 24h moves, suggesting a pattern of selling into good news.
Over the last few months, Repligen has combined solid fundamentals with active investor outreach. On Oct 28, 2025, it reported strong Q3 results and raised FY2025 guidance, yet the stock fell 5.92% in 24 hours. Product innovation continued with new chromatography resins announced on Dec 16, 2025, which also saw a negative price reaction. Multiple conference appearances in October–November showed a strategy of consistent visibility, and today’s J.P. Morgan conference participation fits that ongoing outreach pattern.
Market Pulse Summary
This announcement highlights Repligen’s plan to present at the J.P. Morgan 2026 Healthcare Conference, continuing a pattern of frequent investor conference participation. The company recently reported strong Q3 2025 results and launched new chromatography resins, yet past news often saw short-term share pressure. Investors may focus on any incremental detail shared at the conference that builds on prior earnings, product launches, and capital allocation disclosures.
Jargon Translator
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT.
A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
Repligen Contact:
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com
FAQ
When will Repligen (RGEN) present at the J.P. Morgan 2026 Healthcare Conference?
Who will present for Repligen (RGEN) at the J.P. Morgan 2026 Healthcare Conference?
How can investors watch Repligen's (RGEN) presentation at J.P. Morgan 2026?
Will Repligen's (RGEN) J.P. Morgan 2026 presentation be available after the event?
What are the dates of the J.P. Morgan 2026 Healthcare Conference where RGEN will appear?
